Century Therapeutics, LLC
3675 Market Street, Suite 200
Philadelphia
PA
19104
United States
Website: https://www.centurytx.com/
About Century Therapeutics, LLC
Our genetically-engineered, universal iPSCs-derived immune effector cell products (NK, T, Dendritic cells, and macrophage) are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care.
19 articles with Century Therapeutics, LLC
-
Century Therapeutics Announces Pricing of Initial Public Offering
6/17/2021
Century Therapeutics, an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the pricing of its initial public offering of 10,550,000 shares of its common stock at a public offering price of $20.00 per share
-
Century Therapeutics Adds Respected Biotech Executives to Board of Directors
6/1/2021
Century Therapeutics , a leading cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Alessandro Riva , M.D., and Kimberly Blackwell, M.D., as new Independent Directors.
-
BioSpace Movers & Shakers, May 7
5/7/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Century Therapeutics Expands Board of Directors with Key Appointments
5/5/2021
Pharmaceutical industry veteran Joe Jimenez appointed Board Chair Cynthia Butitta joins as Independent Director
-
Money on the Move – March 3-9
3/10/2021
Money flows into life sciences companies on a daily basis. Here’s who’s celebrating this week. -
Century Therapeutics Completes $160 Million Series C Financing to Accelerate Development of iPSC-derived Cell Therapy Pipeline
3/3/2021
Financing led by Casdin Capital and joined by Fidelity Management & Research LLC, the Federated Hermes Kaufmann Funds, RA Capital, Logos Capital, OrbiMed, Marshall Wace, Qatar Investment Authority, Avidity Partners, Octagon Capital, and joined by founding investors Versant Ventures and Leaps by Bayer Capital to expand novel iPSC platform and drive product development
-
Century Therapeutics received a $160 million infusion of cash to advance the company’s pipeline of induced pluripotent stem cell (iPSC)-derived cell therapies for cancer.
-
Century Therapeutics Significantly Expands Capabilities with New Operational, Laboratory and Manufacturing Facilities in Pennsylvania and New Jersey
2/17/2021
Century Therapeutics announced a significant expansion of its operational and laboratory space in Philadelphia, as well as progress on its manufacturing facility in Branchburg, NJ, paving the way for a strong technical foundation as the company scales up its in-house research and development capabilities.
-
BioSpace Movers & Shakers, Sept. 18
9/18/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Century Therapeutics Announces Appointment of Michael C. Diem as Chief Business Officer
9/16/2020
Century Therapeutics , developer of induced pluripotent stem cell (iPSC)-derived allogeneic cell therapies for cancer, today announced the appointment of Michael C. Diem, MD, as Chief Business Officer. Dr. Diem has more than 15 years of experience in the global pharmaceutical and biotech industries and nearly 10 years of experience in academic and clinical medicine. “I am excited to welcome Mike to Century as he shar
-
Century Therapeutics Announces Acquisition of Empirica Therapeutics
6/23/2020
Century Therapeutics Canada will develop induced pluripotent Stem Cell (iPSC)-derived allogeneic immune cell therapies against glioblastoma (GBM)
-
Century Therapeutics Announces Formation of Scientific Advisory Board
5/5/2020
Century Therapeutics, developer of induced pluripotent stem cell -derived allogeneic cell therapies for cancer, announced the formation of its Scientific Advisory Board to include several renowned experts in the fields of developmental and stem cell biology, genetics, and immuno-oncology.
-
Century Therapeutics Announces Opening of Seattle Innovation Hub
3/10/2020
New company site will focus on creating next-gen product candidates to break barriers in the treatment of solid tumors
-
BioSpace Movers and Shakers, Jan. 31
1/31/2020
Pharma and biotech companies strengthen their leadership teams and boards with this week's Movers & Shakers. -
Century Therapeutics Expands Board of Directors and Management Team
1/28/2020
Century Therapeutics, a Versant Ventures-founded developer of next-generation allogeneic cell therapies, today announced the appointments of Joseph Jimenez to its board of directors and Greg Russotti, PhD, as chief technology officer.
-
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.
-
Century Therapeutics Launches With USD 250M Financing for Induced Pluripotent Stem Cell (iPSC) Allogeneic Cell Therapy Platform - July 1, 2019
7/1/2019
Created by Versant Ventures and partnered with Fujifilm to develop iPSC-derived adaptive and innate immune effector cell therapies
-
Century Therapeutics launches with USD 250M financing for induced pluripotent stem cell (iPSC) allogeneic cell therapy platform
7/1/2019
Created by Versant Ventures and partnered with Fujifilm to develop iPSC-derived adaptive and innate immune effector cell therapies
-
Century’s iPSCs, which are stem cells that can be generated from adult stem cells, have unlimited self-renewing capacity, the company said, which enables multiple rounds of cellular engineering.